178 related articles for article (PubMed ID: 37728764)
1. Frequency of actionable secondary findings in 7472 Korean genomes derived from the National Project of Bio Big Data pilot study.
Kim Y; Kim JM; Cho HW; Park HY; Park MH
Hum Genet; 2023 Nov; 142(11):1561-1569. PubMed ID: 37728764
[TBL] [Abstract][Full Text] [Related]
2. Actionable secondary findings following exome sequencing of 836 non-obstructive azoospermia cases and their value in patient management.
Kasak L; Lillepea K; Nagirnaja L; Aston KI; Schlegel PN; Gonçalves J; Carvalho F; Moreno-Mendoza D; Almstrup K; Eisenberg ML; Jarvi KA; O'Bryan MK; Lopes AM; Conrad DF; ; Punab M; Laan M
Hum Reprod; 2022 Jun; 37(7):1652-1663. PubMed ID: 35535697
[TBL] [Abstract][Full Text] [Related]
3. Frequency and spectrum of actionable pathogenic secondary findings in 196 Korean exomes.
Jang MA; Lee SH; Kim N; Ki CS
Genet Med; 2015 Dec; 17(12):1007-11. PubMed ID: 25856671
[TBL] [Abstract][Full Text] [Related]
4. Actionable secondary findings in the 73 ACMG-recommended genes in 1559 Thai exomes.
Chetruengchai W; Shotelersuk V
J Hum Genet; 2022 Mar; 67(3):137-142. PubMed ID: 34621001
[TBL] [Abstract][Full Text] [Related]
5. Secondary genomic findings in the 2020 China Neonatal Genomes Project participants.
Xiao H; Zhang JT; Dong XR; Lu YL; Wu BB; Wang HJ; Zhao ZY; Yang L; Zhou WH
World J Pediatr; 2022 Oct; 18(10):687-694. PubMed ID: 35727495
[TBL] [Abstract][Full Text] [Related]
6. Frequency of genomic secondary findings among 21,915 eMERGE network participants.
eMERGE Clinical Annotation Working Group
Genet Med; 2020 Sep; 22(9):1470-1477. PubMed ID: 32546831
[TBL] [Abstract][Full Text] [Related]
7. The ACMG SF v3.0 gene list increases returnable variant detection by 22% when compared with v2.0 in the ClinSeq cohort.
Johnston JJ; Brennan ML; Radenbaugh B; Yoo SJ; Hernandez SM; ; Lewis KL; Katz AE; Manolio TA; Biesecker LG
Genet Med; 2022 Mar; 24(3):736-743. PubMed ID: 34906458
[TBL] [Abstract][Full Text] [Related]
8. Landscape of Secondary Findings in Chinese Population: A Practice of ACMG SF v3.0 List.
Huang Y; Liu B; Shi J; Zhao S; Xu K; Sun L; Chen N; Tian W; Zhang J; Wu N
J Pers Med; 2022 Sep; 12(9):. PubMed ID: 36143288
[TBL] [Abstract][Full Text] [Related]
9. The rate of secondary genomic findings in the Saudi population.
Aloraini T; Alsubaie L; Alasker S; Al Muitiri A; Alswaid A; Eyiad W; Al Mutairi F; Ababneh F; Alfadhel M; Alfares A
Am J Med Genet A; 2022 Jan; 188(1):83-88. PubMed ID: 34515413
[TBL] [Abstract][Full Text] [Related]
10. Physician-directed genetic screening to evaluate personal risk for medically actionable disorders: a large multi-center cohort study.
Haverfield EV; Esplin ED; Aguilar SJ; Hatchell KE; Ormond KE; Hanson-Kahn A; Atwal PS; Macklin-Mantia S; Hines S; Sak CW; Tucker S; Bleyl SB; Hulick PJ; Gordon OK; Velsher L; Gu JYJ; Weissman SM; Kruisselbrink T; Abel C; Kettles M; Slavotinek A; Mendelsohn BA; Green RC; Aradhya S; Nussbaum RL
BMC Med; 2021 Aug; 19(1):199. PubMed ID: 34404389
[TBL] [Abstract][Full Text] [Related]
11. The burden of pathogenic variants in clinically actionable genes in a founder population.
Lynch MT; Maloney KA; Pollin TI; Streeten EA; Xu H; ; Shuldiner AR; Van Hout CV; Gonzaga-Jauregui C; Mitchell BD
Am J Med Genet A; 2021 Nov; 185(11):3476-3484. PubMed ID: 34467620
[TBL] [Abstract][Full Text] [Related]
12. Actionable secondary findings in arrhythmogenic right ventricle cardiomyopathy genes: impact and challenge of genetic counseling.
Abicht A; Schön U; Laner A; Holinski-Feder E; Diebold I
Cardiovasc Diagn Ther; 2021 Apr; 11(2):637-649. PubMed ID: 33968641
[TBL] [Abstract][Full Text] [Related]
13. Identification of Medically Actionable Secondary Findings in the 1000 Genomes.
Olfson E; Cottrell CE; Davidson NO; Gurnett CA; Heusel JW; Stitziel NO; Chen LS; Hartz S; Nagarajan R; Saccone NL; Bierut LJ
PLoS One; 2015; 10(9):e0135193. PubMed ID: 26332594
[TBL] [Abstract][Full Text] [Related]
14. Actionable genomic variants in 6045 participants from the Qatar Genome Program.
Elfatih A; Mifsud B; Syed N; Badii R; Mbarek H; Abbaszadeh F; ; Estivill X
Hum Mutat; 2021 Aug; ():. PubMed ID: 34428338
[TBL] [Abstract][Full Text] [Related]
15. Secondary findings in a large Pakistani cohort tested with whole genome sequencing.
Skrahin A; Cheema HA; Hussain M; Rana NN; Rehman KU; Kumar R; Oprea G; Ameziane N; Rolfs A; Skrahina V
Life Sci Alliance; 2023 Mar; 6(3):. PubMed ID: 36635046
[TBL] [Abstract][Full Text] [Related]
16. Actionable Genotypes and Their Association with Life Span in Iceland.
Jensson BO; Arnadottir GA; Katrinardottir H; Fridriksdottir R; Helgason H; Oddsson A; Sveinbjornsson G; Eggertsson HP; Halldorsson GH; Atlason BA; Jonsson H; Oskarsson GR; Sturluson A; Gudjonsson SA; Thorisson GA; Zink F; Moore KHS; Palsson G; Sigurdsson A; Jonasdottir A; Jonasdottir A; Magnusson MK; Helgadottir A; Steinthorsdottir V; Gudmundsson J; Stacey SN; Hilmarsson R; Olafsson I; Johannsson OT; Arnar DO; Saemundsdottir J; Magnusson OT; Masson G; Halldorsson BV; Helgason A; Stefansson H; Jonsdottir I; Holm H; Rafnar T; Thorsteinsdottir U; Gudbjartsson DF; Stefansson K; Sulem P
N Engl J Med; 2023 Nov; 389(19):1741-1752. PubMed ID: 37937776
[TBL] [Abstract][Full Text] [Related]
17. High-frequency actionable pathogenic exome variants in an average-risk cohort.
Rego S; Dagan-Rosenfeld O; Zhou W; Sailani MR; Limcaoco P; Colbert E; Avina M; Wheeler J; Craig C; Salins D; Röst HL; Dunn J; McLaughlin T; Steinmetz LM; Bernstein JA; Snyder MP
Cold Spring Harb Mol Case Stud; 2018 Dec; 4(6):. PubMed ID: 30487145
[TBL] [Abstract][Full Text] [Related]
18. A systematic literature review of disclosure practices and reported outcomes for medically actionable genomic secondary findings.
Sapp JC; Facio FM; Cooper D; Lewis KL; Modlin E; van der Wees P; Biesecker LG
Genet Med; 2021 Dec; 23(12):2260-2269. PubMed ID: 34433902
[TBL] [Abstract][Full Text] [Related]
19. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics.
Kalia SS; Adelman K; Bale SJ; Chung WK; Eng C; Evans JP; Herman GE; Hufnagel SB; Klein TE; Korf BR; McKelvey KD; Ormond KE; Richards CS; Vlangos CN; Watson M; Martin CL; Miller DT
Genet Med; 2017 Feb; 19(2):249-255. PubMed ID: 27854360
[TBL] [Abstract][Full Text] [Related]
20. Identification of a Novel BRCA1 Pathogenic Mutation in Korean Patients Following Reclassification of BRCA1 and BRCA2 Variants According to the ACMG Standards and Guidelines Using Relevant Ethnic Controls.
Park JS; Nam EJ; Park HS; Han JW; Lee JY; Kim J; Kim TI; Lee ST
Cancer Res Treat; 2017 Oct; 49(4):1012-1021. PubMed ID: 28111427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
